King's College London

Research portal

Gaps and challenges: WHO treatment recommendations for tobacco cessation and management of substance use disorders in people with severe mental illness

Research output: Contribution to journalArticle

Standard

Gaps and challenges : WHO treatment recommendations for tobacco cessation and management of substance use disorders in people with severe mental illness. / Das-Munshi, Jayati; Semrau, Maya; Barbui, Corrado; Chowdhary, Neerja; Gronholm, Petra C.; Kolappa, Kavitha; Krupchanka, Dzmitry; Dua, Tarun; Thornicroft, Graham.

In: BMC Psychiatry, Vol. 20, No. 1, 237, 14.05.2020.

Research output: Contribution to journalArticle

Harvard

Das-Munshi, J, Semrau, M, Barbui, C, Chowdhary, N, Gronholm, PC, Kolappa, K, Krupchanka, D, Dua, T & Thornicroft, G 2020, 'Gaps and challenges: WHO treatment recommendations for tobacco cessation and management of substance use disorders in people with severe mental illness', BMC Psychiatry, vol. 20, no. 1, 237. https://doi.org/10.1186/s12888-020-02623-y

APA

Das-Munshi, J., Semrau, M., Barbui, C., Chowdhary, N., Gronholm, P. C., Kolappa, K., Krupchanka, D., Dua, T., & Thornicroft, G. (2020). Gaps and challenges: WHO treatment recommendations for tobacco cessation and management of substance use disorders in people with severe mental illness. BMC Psychiatry, 20(1), [237]. https://doi.org/10.1186/s12888-020-02623-y

Vancouver

Das-Munshi J, Semrau M, Barbui C, Chowdhary N, Gronholm PC, Kolappa K et al. Gaps and challenges: WHO treatment recommendations for tobacco cessation and management of substance use disorders in people with severe mental illness. BMC Psychiatry. 2020 May 14;20(1). 237. https://doi.org/10.1186/s12888-020-02623-y

Author

Das-Munshi, Jayati ; Semrau, Maya ; Barbui, Corrado ; Chowdhary, Neerja ; Gronholm, Petra C. ; Kolappa, Kavitha ; Krupchanka, Dzmitry ; Dua, Tarun ; Thornicroft, Graham. / Gaps and challenges : WHO treatment recommendations for tobacco cessation and management of substance use disorders in people with severe mental illness. In: BMC Psychiatry. 2020 ; Vol. 20, No. 1.

Bibtex Download

@article{14e0555ff0ef43298376d1128ac1da25,
title = "Gaps and challenges: WHO treatment recommendations for tobacco cessation and management of substance use disorders in people with severe mental illness",
abstract = "Background: People with severe mental disorders (SMD) experience premature mortality mostly from preventable physical causes. The World Health Organization (WHO) have recently produced guidelines on the management of physical health conditions in SMD. This paper presents the evidence which led to the recommendations for tobacco cessation and management of substance use disorders in SMD. Methods: Scoping reviews informed 2 PICO (Population Intervention, Comparator, Outcome) questions relating to tobacco cessation and management of substance use disorders in SMD. Systematic searches led to the identification of systematic reviews with relevant evidence to address these questions. Retrieved evidence was assessed using GRADE methodology, informing the development of guidelines. Results: One thousand four hundred thirty-four records were identified through systematic searches for SMD and tobacco cessation, of which 4 reviews were included in GRADE tables and 18 reviews in narrative synthesis. For SMD and substance use disorders, 4268 records were identified, of which 4 studies from reviews were included in GRADE tables and 16 studies in narrative synthesis. People with SMD who use tobacco should be offered combined pharmacological (Varenicline, Bupropion or Nicotine Replacement Therapy) and non-pharmacological interventions such as tailored directive and supportive behavioural interventions. For people with SMD and substance use disorders (drug and/or alcohol), interventions should be considered in accordance with WHO mhGAP guidelines. Prescribers should note potential drug-drug interactions. Recommendation were conditional and based on low/very low certainty of evidence with a scarcity of evidence from low- and middle-income settings. Conclusions: These guidelines mark an important step towards addressing premature mortality in people with SMD. The dearth of high-quality evidence and evidence from LMIC settings must inform the future research agenda. Guidelines: https://www.who.int/mental_health/evidence/guidelines_physical_health_and_severe_mental_disorders/en https://www.who.int/publications-detail/mhgap-intervention-guide%2D%2D-version-2.0",
keywords = "Bipolar affective disorders, Depression, Deprivation, Ethnicity, Life expectancy, Mortality, Schizoaffective disorders, Schizophrenia, Serious mental illness, Severe mental illness",
author = "Jayati Das-Munshi and Maya Semrau and Corrado Barbui and Neerja Chowdhary and Gronholm, {Petra C.} and Kavitha Kolappa and Dzmitry Krupchanka and Tarun Dua and Graham Thornicroft",
year = "2020",
month = may,
day = "14",
doi = "10.1186/s12888-020-02623-y",
language = "English",
volume = "20",
journal = "BMC Psychiatry",
issn = "1471-244X",
publisher = "BioMed Central",
number = "1",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Gaps and challenges

T2 - WHO treatment recommendations for tobacco cessation and management of substance use disorders in people with severe mental illness

AU - Das-Munshi, Jayati

AU - Semrau, Maya

AU - Barbui, Corrado

AU - Chowdhary, Neerja

AU - Gronholm, Petra C.

AU - Kolappa, Kavitha

AU - Krupchanka, Dzmitry

AU - Dua, Tarun

AU - Thornicroft, Graham

PY - 2020/5/14

Y1 - 2020/5/14

N2 - Background: People with severe mental disorders (SMD) experience premature mortality mostly from preventable physical causes. The World Health Organization (WHO) have recently produced guidelines on the management of physical health conditions in SMD. This paper presents the evidence which led to the recommendations for tobacco cessation and management of substance use disorders in SMD. Methods: Scoping reviews informed 2 PICO (Population Intervention, Comparator, Outcome) questions relating to tobacco cessation and management of substance use disorders in SMD. Systematic searches led to the identification of systematic reviews with relevant evidence to address these questions. Retrieved evidence was assessed using GRADE methodology, informing the development of guidelines. Results: One thousand four hundred thirty-four records were identified through systematic searches for SMD and tobacco cessation, of which 4 reviews were included in GRADE tables and 18 reviews in narrative synthesis. For SMD and substance use disorders, 4268 records were identified, of which 4 studies from reviews were included in GRADE tables and 16 studies in narrative synthesis. People with SMD who use tobacco should be offered combined pharmacological (Varenicline, Bupropion or Nicotine Replacement Therapy) and non-pharmacological interventions such as tailored directive and supportive behavioural interventions. For people with SMD and substance use disorders (drug and/or alcohol), interventions should be considered in accordance with WHO mhGAP guidelines. Prescribers should note potential drug-drug interactions. Recommendation were conditional and based on low/very low certainty of evidence with a scarcity of evidence from low- and middle-income settings. Conclusions: These guidelines mark an important step towards addressing premature mortality in people with SMD. The dearth of high-quality evidence and evidence from LMIC settings must inform the future research agenda. Guidelines: https://www.who.int/mental_health/evidence/guidelines_physical_health_and_severe_mental_disorders/en https://www.who.int/publications-detail/mhgap-intervention-guide%2D%2D-version-2.0

AB - Background: People with severe mental disorders (SMD) experience premature mortality mostly from preventable physical causes. The World Health Organization (WHO) have recently produced guidelines on the management of physical health conditions in SMD. This paper presents the evidence which led to the recommendations for tobacco cessation and management of substance use disorders in SMD. Methods: Scoping reviews informed 2 PICO (Population Intervention, Comparator, Outcome) questions relating to tobacco cessation and management of substance use disorders in SMD. Systematic searches led to the identification of systematic reviews with relevant evidence to address these questions. Retrieved evidence was assessed using GRADE methodology, informing the development of guidelines. Results: One thousand four hundred thirty-four records were identified through systematic searches for SMD and tobacco cessation, of which 4 reviews were included in GRADE tables and 18 reviews in narrative synthesis. For SMD and substance use disorders, 4268 records were identified, of which 4 studies from reviews were included in GRADE tables and 16 studies in narrative synthesis. People with SMD who use tobacco should be offered combined pharmacological (Varenicline, Bupropion or Nicotine Replacement Therapy) and non-pharmacological interventions such as tailored directive and supportive behavioural interventions. For people with SMD and substance use disorders (drug and/or alcohol), interventions should be considered in accordance with WHO mhGAP guidelines. Prescribers should note potential drug-drug interactions. Recommendation were conditional and based on low/very low certainty of evidence with a scarcity of evidence from low- and middle-income settings. Conclusions: These guidelines mark an important step towards addressing premature mortality in people with SMD. The dearth of high-quality evidence and evidence from LMIC settings must inform the future research agenda. Guidelines: https://www.who.int/mental_health/evidence/guidelines_physical_health_and_severe_mental_disorders/en https://www.who.int/publications-detail/mhgap-intervention-guide%2D%2D-version-2.0

KW - Bipolar affective disorders

KW - Depression

KW - Deprivation

KW - Ethnicity

KW - Life expectancy

KW - Mortality

KW - Schizoaffective disorders

KW - Schizophrenia

KW - Serious mental illness

KW - Severe mental illness

UR - http://www.scopus.com/inward/record.url?scp=85085127267&partnerID=8YFLogxK

U2 - 10.1186/s12888-020-02623-y

DO - 10.1186/s12888-020-02623-y

M3 - Article

AN - SCOPUS:85085127267

VL - 20

JO - BMC Psychiatry

JF - BMC Psychiatry

SN - 1471-244X

IS - 1

M1 - 237

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454